In its latest SEC filing, Virginia Retirement Systems et al. raised its position in Johnson & Johnson by 12.3% during the third quarter, acquiring an additional 127,100 shares to bring its total holding to 1,158,903 shares. This stake represents 1.4% of the fund’s portfolio and is now its ninth largest position. At the end of the reporting period, the investment was valued at approximately $214.9 million, reflecting the fund’s confidence in J&J’s diversified healthcare operations across pharmaceuticals, medical devices and consumer health segments.

For the quarter ended August 30, Johnson & Johnson reported earnings per share of $2.26 on revenues of $24.02 billion, delivering a net margin of 27.26% and a return on equity of 32.73%. The company generated roughly $14 billion in free cash flow through the first three quarters of its fiscal year, comfortably covering dividends of $9.3 billion. In early Q1 of 2026, the board declared a cash dividend of $1.30 per share, marking a 50.19% payout ratio and an annualized yield of 2.5%. The dividend is payable on March 10, 2026 to shareholders of record as of February 24, 2026.

Johnson & Johnson’s consensus rating stands at "Moderate Buy" based on data from MarketBeat, with four analysts assigning a Strong Buy, fourteen a Buy and nine a Hold. Recent target price revisions have trended upward: Bank of America lifted its target from 204 to 220, Barclays increased its forecast from 197 to 217, and Stifel Nicolaus raised its estimate from 165 to 190. The average analyst target price is 211.25, suggesting further upside potential driven by steady earnings growth projections of 10.58 EPS for the current fiscal year and J&J’s resilient balance sheet, which includes a debt-to-equity ratio of 0.50 and investment-grade credit ratings.